Collegium Pharmaceutical (NASDAQ:COLL) Earns “Buy” Rating from William Blair

Share on StockTwits

William Blair reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a report issued on Tuesday morning, TipRanks reports. William Blair also issued estimates for Collegium Pharmaceutical’s Q1 2020 earnings at $0.08 EPS, Q2 2020 earnings at $0.17 EPS, Q3 2020 earnings at $0.33 EPS and Q4 2020 earnings at ($0.02) EPS.

A number of other research firms have also recently weighed in on COLL. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Thursday, August 8th. ValuEngine upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Thursday, August 1st. Cantor Fitzgerald reiterated an overweight rating and issued a $24.00 target price (down from $35.00) on shares of Collegium Pharmaceutical in a research note on Thursday, August 8th. Finally, BidaskClub upgraded shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $24.33.

Shares of NASDAQ:COLL traded down $0.01 during trading on Tuesday, reaching $11.63. The stock had a trading volume of 257,104 shares, compared to its average volume of 360,442. Collegium Pharmaceutical has a one year low of $10.01 and a one year high of $19.83. The company has a market capitalization of $391.10 million, a P/E ratio of -9.77 and a beta of 0.52. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 0.23. The firm’s 50-day simple moving average is $11.36 and its 200 day simple moving average is $13.12.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The business had revenue of $75.04 million for the quarter, compared to analysts’ expectations of $75.77 million. During the same period last year, the business earned ($0.40) EPS. The company’s revenue was up 2.7% compared to the same quarter last year. Equities research analysts forecast that Collegium Pharmaceutical will post -0.36 earnings per share for the current fiscal year.

In related news, Director David Hirsch sold 22,106 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the sale, the director now directly owns 64,223 shares in the company, valued at approximately $748,197.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 2,857 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $12.31, for a total transaction of $35,169.67. Following the completion of the sale, the executive vice president now owns 40,596 shares of the company’s stock, valued at $499,736.76. The disclosure for this sale can be found here. Insiders sold a total of 49,963 shares of company stock valued at $574,205 over the last quarter. 8.08% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its stake in Collegium Pharmaceutical by 19.1% during the 2nd quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after acquiring an additional 693,812 shares during the period. BlackRock Inc. lifted its stake in Collegium Pharmaceutical by 7.1% during the 2nd quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after acquiring an additional 165,018 shares during the period. Vanguard Group Inc. lifted its stake in Collegium Pharmaceutical by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,571,474 shares of the specialty pharmaceutical company’s stock valued at $20,665,000 after acquiring an additional 22,883 shares during the period. Rice Hall James & Associates LLC lifted its stake in Collegium Pharmaceutical by 5.8% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,260,690 shares of the specialty pharmaceutical company’s stock valued at $16,578,000 after acquiring an additional 69,549 shares during the period. Finally, Cortina Asset Management LLC lifted its stake in Collegium Pharmaceutical by 81.0% during the 2nd quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after acquiring an additional 228,035 shares during the period. Institutional investors and hedge funds own 92.08% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

See Also: What does a neutral rating on stocks mean?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.